Sandra Calvin, SVP, CHIEF ACCOUNTING OFFICER at Travere Therapeutics, Inc. (TVTX), sold 7,402 shares at $40.00 ($296K) on 2025-12-24, disclosed to the SEC on 2025-12-29.
Scheduled sale ($296k) by SVP, CHIEF ACCOUNTING OFFICER under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| Filing → |
| TVTX | SELL | 2026-02-03 | $139K | — | Filing → |
| TVTX | SELL | 2025-12-16 | $105K | — | Filing → |
| TVTX | SELL | 2025-11-06 | $2.4M | — | Filing → |